Although loss-of-function mutations of Trem2 are rare in humans, microglia genes seem in general (26) to have a high impact on AD pathology, and modulation of microglial function is being intensively studied as a therapeutic strategy for AD (27). This evidence concerns the gene TREM2 and Alzheimer disease.